Epidermolysis Bullosa spontaneaous blistering
Conditions
Interventions
INM-755 cream (high concentration, 0.3%), INM-755 cream (low concentration,
0.03%), or matching vehicle.
Sponsors
InMed Pharmaceuticals Inc.
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Male or female subject between 18 and 45 years of age inclusive at the time of consent. 2. Body mass index (BMI) between 18 and 30 kg/m2, inclusive 3. Subject is in good general health, according to the investigator*s judgment based on vital signs, medical history, physical examination, and laboratory tests performed. 4. Contraception: a. Male participants: i. A male participant who agrees to follow the contraceptive guidance during their participation in this study from at least 4 weeks before Day 1 until at least 4 weeks after the last study product administration. Effective contraceptive methods are described in the protocol b. Female participants: i. A female participant is eligible to participate if she is not pregnant, does not plan to become pregnant during the study, not breastfeeding, and at least 1 of the following conditions applies: 1. Not a woman of child-bearing potential (WOCBP) OR 2. A WOCBP who agrees to follow the contraceptive guidance during their participation in this study from at least 4 weeks before Day 1 until at least 4 weeks after the last study product administration. Effective contraceptive methods are described in Section 4.5.1. 5. Female subject has had a negative urine pregnancy test at screening and at Day 1 before dosing. 6. Subject is willing to participate and is capable of giving informed consent. 7. Subjects must be willing to comply with all study procedures, have the ability to communicate well with the investigator in the Dutch language and must be available for the duration of the study. 8. Subject has sufficient application area of healthy intact skin of the back.
Exclusion criteria
Exclusion criteria: A subject who meets any of the following criteria at screening and at Day 1 before dosing, unless specified otherwise, will be excluded from participation in this study: 1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study. 2. Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments. 3. Subject has presence of or has a history of atopic dermatitis or psoriasis. 4. Any known allergy or hypersensitivity to medical adhesives (e.g., Tegaderm) used in this study or any component of the study product (e.g. Poloxamers, Lecithin, Isopropyl Palmitate). 5. Subject has presence of any tattoos, scratches, open sores, excessive hair, or skin damages in the target treatment area(s) that, in the opinion of the investigator, may interfere with study evaluations. 6. Subject has a Fitzpatrick*s Skin Phototype *4. 7. Subject is known to have immune deficiency or is immunocompromised. 8. Subject has a known history of chronic infectious disease (eg, hepatitis B, hepatitis C, or infection with human immunodeficiency virus). 9. Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Subjects with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded. 10. Subject had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study. 11. Subject has any clinically significant medical condition or physical, laboratory, ECG, or vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results. 12. Subject has used any systemic treatment that could be immunosuppressive (including oral corticosteroids, oral retinoids, immunosuppressive medication, methotrexate, cyclosporine, or apremilast) within 4 weeks prior to Day 1. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed. 13. Subject has had excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths within 4 weeks prior to Day 1 or is not willing to minimize natural and artificial sunlight exposure during the study. Use of sunscreen products (except on application areas) and protective apparel are recommended when sun exposure cannot be avoided. 14. Subject has received laser treatment, electrolysis on the application areas within 4 weeks prior to Day 1 or is planning to during the study period. 15. Subject has shaved the application area 72 hours prior to Day 1, or is planning to do so during the study period. 16. Subject has used cannabis or any cannabinoid products within 12 weeks prior to Day 1. 17. Subject has used any medication known to impair alertness and/or ability to detect discomfort within 1 week prior to Day 1. 18. Subject has used a topical applied treatment on the targeted application area(s) within 1 week prior to Day 1. 19. Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1. 20. Subject has a positive screen result for drug of abuse at screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tolerability / safety endpoints for Part 1 Objectives * Incidence of local and systemic treatment-emergent adverse events (TEAEs) * Changes in vital signs, ECG, safety laboratory tests, erythema, and local tolerability assessment Pharmacokinetic endpoints for Part 1 Objectives * Measurement of plasma concentrations of INM-755. * Measurement of skin concentration of INM-755. | — |
Secondary
| Measure | Time frame |
|---|---|
| Additional endpoints for Part 1 Objectives * Change from baseline over time in Bond-Lader visual analogue scale (Mood Rating Scale) (BL-VAS) and Bowdle VAS (B-VAS) Wound Healing Endpoints for Part 2 Objective * Wound characteristics by LSCI, OCT, TEWL and 3D photographyand * Wound closure over time | — |
Countries
Netherlands
Outcome results
None listed